Related Experiment Video
Updated: May 10, 2025
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.6K
Large-scale human myeloma cell line small molecule compound screen dataset
V Keith Hughitt1, John K Simmons1,2, Sayeh Gorjifard1,3
1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Scientific Data
|April 19, 2025
Summary
Researchers screened 1,912 small molecules against 47 human myeloma cell lines to find new treatments for multiple myeloma (a type of blood cancer). This large-scale drug screen provides valuable data for identifying novel therapeutic agents and biomarkers.
Area of Science:
- Hematology
- Pharmacology
- Oncology
Background:
- Multiple myeloma is the second most common blood cancer, characterized by incurable B-cell malignancy and frequent relapse.
- Recent therapeutic advances have improved survival, yet effective treatments remain elusive.
Purpose of the Study:
- To identify novel therapeutic agents for multiple myeloma.
- To discover biomarkers associated with differential treatment responses.
Main Methods:
- Conducted a large-scale pharmacological screen of 1,912 small molecule compounds.
- Tested compounds across 11 doses against 47 human myeloma cell lines (HMCL).
Main Results:
- Generated a comprehensive dataset from the drug screen, including raw and processed data.
- Provided drug and cell line metadata and high-level feature characterization.
Conclusions:
- The study provides a valuable resource for multiple myeloma research.
- The dataset and associated workflow facilitate the discovery of new drugs and predictive biomarkers for this hematological malignancy.
